Modulation of clearance of recombinant serum albumin by either glycosylation or truncation
Research article published in Thrombosis research (2000)
Abstract
Albumin is an abundant non-glycosylated plasma protein with a slow clearance profile. It has been employed as a fusion partner in efforts to slow the clearance of small antithrombotic proteins like hirudin. In the present study, the in vivo clearance of recombinant rabbit serum albumin (rRSA), of mutant rRSAs containing consensus sequences for N-linked glycosylation (D494N and V14T variants), and of mutant mini-proteins truncated at albumin domain boundaries (rRSAs 1-185, 1-377, or 378-584) was examined. Mean terminal catabolic half-lives (t(0.5)cat) in rabbits for plasma-derived RSA, rRSA, and the V14T variant did not differ significantly (range 4. 32-4.76 days). In contrast, mean t(0.5)cat was reduced to 2.87 days for the D494N variant and to less than 0.071 days for all mini-proteins. The mini-proteins were found in the urine in tissue distribution experiments, suggesting a renal route of clearance. Our results suggest that all three internally repeated albumin domains are required to maintain the slow in vivo clearance profile of albumin, and that albumin glycosylation can be associated with an acceleration of clearance. This information could be used to design fusion proteins, including those with antithrombotic properties, with predictably altered in vivo half-lives less than that of serum albumin.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Albumin is an abundant non-glycosylated plasma protein with a slow clearance profile.
Why This Matters for Hirudotherapy
This study examined how glycosylation and domain truncation affect the in vivo clearance of recombinant rabbit serum albumin (rRSA) in rabbits, finding that all three internally repeated albumin domains are required to maintain albumin's slow clearance profile and that introduced glycosylation (D494N variant) accelerated clearance, reducing half-life from ~4.3 to 2.87 days. The authors note that albumin has been used as a fusion partner to slow clearance of small antithrombotic proteins like hirudin, and that their findings could inform the design of such fusion proteins with predictably altered half-lives. The study is relevant to ASH's domain insofar as it provides pharmacokinetic design principles applicable to hirudin-based therapeutics, though it does not directly involve hirudin, leeches, or any leech-derived molecule.
Citation
Modulation of clearance of recombinant serum albumin by either glycosylation or truncation
Sheffield WP et al. · Thrombosis research, 2000
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026